Roivant Sciences Ltd. ROIV
36.62 USD -1.61 (-4.21%)
At closeNov 5, 2026, 6:51 PM EST
36.91 +0.29 +0.81%
After hours · Nov 5, 6:51 PM ET
36.51 Day range 38.27
19.79 52-week range 42.50
- YTD
- +68.76%
- 1 year
- +81.02%
Financial health
Altman Z-Score
42.07 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
0 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
Rating
C2 / 5 overall
- DCF 2
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 1
Valuation
P/E -64.4×
FY 2019 5y median -5.2× FY 2025
P/S 2327×
FY 2019 5y median 250× FY 2025
P/B 4.2×
FY 2019 5y median 2.0× FY 2025
P/FCF -25.3×
FY 2019 5y median -8.7× FY 2025
EV/EBITDA -68.5×
FY 2019 5y median -4.8× FY 2025
EV/Sales 2168×
FY 2019 5y median 129× FY 2025
FCF Yield -3.9%
FY 2019 5y median -11.5% FY 2025
Profitability
Gross Margin 84.4%
FY 2019 5y median 90.4% FY 2025
Operating Margin -15560.6%
FY 2019 5y median -2565.9% FY 2025
Net Margin -3629.2%
FY 2019 5y median -1528.9% FY 2025
ROE -6.6%
FY 2019 5y median -6.6% FY 2025
ROIC -23.5%
FY 2019 5y median -23.5% FY 2025
ROA -5.2%
FY 2019 5y median -5.2% FY 2025
Growth (YoY)
Revenue -71.6%
FY 2019 FY 2025
Operating Income -15.4%
FY 2019 FY 2025
EPS (diluted) -79.2%
FY 2019 FY 2025
Free Cash Flow 10.1%
FY 2019 FY 2025
Financial Health
Current Ratio 18.4×
FY 2019 5y median 18.4× FY 2025
Quick Ratio 18.4×
FY 2019 5y median 18.4× FY 2025
Debt / Equity 0.0×
FY 2019 5y median 0.1× FY 2025
Net Debt / EBITDA 5.0×
FY 2019 5y median 2.0× FY 2025
Interest Coverage 0.0×
FY 2019 5y median -23.7× FY 2025
Dividends
Dividend Yield 0.0%
FY 2019 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2019 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2026-03-31
